Caldera Medical, a women’s health medical device company, today announced the completion of its acquisition of Atlantic Therapeutics, a provider of non-invasive pelvic floor strengthening and nerve stimulation solutions for women. Caldera solely focuses on medical devices for women’s health, manufacturing and marketing surgical products for the treatment of stress urinary incontinence, pelvic organ prolapse polyps, and fibroids. Atlantic, which is based in Ireland, specializes in the development of medical devices, related software, and connected health technologies primarily to treat incontinence, and sexual health dysfunctions.
Caldera’s portfolio includes its Desara family of surgical products to treat stress urinary incontinence, the Vertessa Lite polypropylene mesh for the treatment of pelvic organ prolapse, and the Benesta system for in-office polyp removal.
Through the acquisition, Caldera adds Atlantic’s FDA-cleared Innovo device to its existing portfolio. The Innovo device is a urinary incontinence treatment option for at-home use where the user puts on the Innovo multipath shorts which contain electrical muscle stimulation technology connected to a remote-like controller. Through a 30-minute session, Innovo completes 180 pelvic floor contractions, helping to re-educate the muscles and make them stronger. Those stronger muscles have more control over the bladder. The device is currently priced at €399 for the starter kit, which includes the multipath shorts, prep spray, and controller.
"We are thrilled to acquire Atlantic Therapeutics and scale the rapidly growing Innovo products worldwide," said Bryon Merade, CEO of Caldera, in a press release announcing the acquisition completion. "This acquisition aligns perfectly with our mission and allows us to offer an even more comprehensive suite of solutions to healthcare providers and patients alike."
Caldera will maintain a European headquarters and innovation center in Galway, Ireland.